QVT Financial’s Investments, Performance, Letters

2. Myovant Sciences Ltd (NYSE:MYOV)

Myovant Sciences Ltd (NYSE:MYOV) is another subsidiary of Roivant Sciences, which was formed in partnership with Takeda Pharmaceuticals. QVT is deemed to own 37.23 million shares of Myovant worth $435.61 million through its interests in Roivant. Myovant Sciences Ltd (NYSE:MYOV) was floated in October 2016 and its stock has inched up by around 4% since the IPO. Similar to the previous year’s Axovant Sciences Ltd (NYSE:AXON) IPO, Myovant Sciences Ltd (NYSE:MYOV) was the largest biotech public offering of 2016. Myovant Sciences is also a late-stage biotechnology company engaged in developing therapies for women’s health and prostate cancer. The company’s main drug is relugolix, which can be used in treatment of uterine fibroids and prostate cancer. The drug is currently in its Phase 3 trials, expected to be completed within the next year.